QUALITY OF LIFE OF PATIENTS TREATED FOR HORMONALLY ACTIVE PITUITARY ADENOMA

Abstract

Dyussembekov Yermek Kavtaevich, Dossanova Ainur Kassimbekovna, Bazarbekova Rimma Bazarbekovna

Adenomas of the pituitary gland represent the most frequent tumors of the chiasmal-sellar region and takes 18%of all brain tumors [1, 22, 25]. Despite the fact that pituitary gland adenomas are benign, 25-55% of them have an invasive growth character, penetrating into surrounding structures [2-4], which undoubtedly affects the quality of their lives. The aim was to study the quality of life of patients receiving various types of therapy for hormonally active adenoma of the pituitary gland (prolactinoma, somatotropinoma, corticotropinoma). We examined 240 patients in dispensary for hormonally active adenoma of the pituitary gland in Almaty polyclinics. Patients with prolactinomas (66.7%), a quarter of patients with somatotropinomas (25%) and the least number of patients with corticotropinomas (8.3%) were frequently examined. Patients with prolactinomas were overwhelmingly on monotherapy with Kabergolin (63.1%), while the rest (36.9%), apart from drug therapy, were subjected to transnasaladenomectomy. All patients with somatotropinomas and corticotropinomas were operated on by trans-nazaltrans-sfenoidaladenomectomy.Medication and radiotherapy were used as additional therapies. The ASBQ questionnaire was used to evaluate the quality of life in patients with hormonally active pituitary adenoma. In general, quality of life in patients with prolactinomas was significantly higher than in other patients.Quality of life before surgery in patients with somatotropinomas was significantly higher but indynamics in 1-3 months and several years after the operation the condition of patients with acromegaly was significantly higher than others.